Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer

Published:2015-01-19 Issue:6 Volume:6 Page:4274-4285
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Liu Donglin¹,Chang Chien-Hsing¹²,Gold David V.³,Goldenberg David M.¹²³

Affiliation:

1. IBC Pharmaceuticals, Inc., Morris Plains, New Jersey 07950, United States of America

2. Immunomedics, Inc., Morris Plains, New Jersey 07950, United States of America

3. Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, New Jersey 07950, United States of America

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biomarkers in pancreatic ductal adenocarcinoma;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

2. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer;Cancer Letters;2023-05

3. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence;International Journal of Molecular Sciences;2023-04-30

4. Mucins as Potential Biomarkers for Early Detection of Cancer;Cancers;2023-03-07

5. Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments;Advanced Therapeutics;2022-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP